EBS

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-3.9M TrimQ1 2026 $3.9M -- $8.24
Jim SimonsRenaissance Technologies $-1.7M TrimQ1 2026 $1.7M -- $8.24
Jim SimonsRenaissance Technologies $-4.6M ExitQ4 2025 $4.6M -- $8.24
Ken GriffinCitadel Advisors $-4.4M ExitQ4 2025 $4.4M -- $8.24
Jim SimonsRenaissance Technologies $2.6M AddQ4 2025 $2.6M -- $8.24
Ken GriffinCitadel Advisors $543.3K AddQ4 2025 $543k -- $8.24

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Steve CohenDemocrat $8.0k OtherDec 11, 2024 $1k-$15k -- $8.24

News

seekingalpha.comEmergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcriptseekingalpha.comJun 8

globenewswire.comEmergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdoseglobenewswire.comJun 4

globenewswire.comEmergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategyglobenewswire.comMay 28

globenewswire.comEmergent BioSolutions to Participate in Upcoming Investor Conferencesglobenewswire.comMay 20

globenewswire.comEmergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]globenewswire.comMay 18

Trade EBS

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

CEO: Joseph C. Papa Jr.
IPO Date: Nov 15, 2006

Market Data

Open: $8.22
High: $8.32
Low: $7.90
Volume: 735K
Avg Volume: 777.7K
52W High: $14.06
52W Low: $5.62

Valuation

Market Cap: $413M
Enterprise Value: $826M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $157M
Revenue: $743M
Net Income: $53M
Cash: $205M
Debt: $572M

Events

EarningsAug 5

EPS est. -0.085